Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options
- PMID: 32161092
- PMCID: PMC7180238
- DOI: 10.1128/JCM.00187-20
Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options
Erratum in
-
Correction for Khan et al., "Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options".J Clin Microbiol. 2020 Jul 23;58(8):e01297-20. doi: 10.1128/JCM.01297-20. Print 2020 Jul 23. J Clin Microbiol. 2020. PMID: 32703895 Free PMC article. No abstract available.
Abstract
The new decade of the 21st century (2020) started with the emergence of a novel coronavirus known as SARS-CoV-2 that caused an epidemic of coronavirus disease (COVID-19) in Wuhan, China. It is the third highly pathogenic and transmissible coronavirus after severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in humans. The source of origin, transmission to humans, and mechanisms associated with the pathogenicity of SARS-CoV-2 are not yet clear, however, its resemblance to SARS-CoV and several other bat coronaviruses was recently confirmed through genome sequencing-related studies. The development of therapeutic strategies is necessary in order to prevent further epidemics and cure infections. In this review, we summarize current information about the emergence, origin, diversity, and epidemiology of three pathogenic coronaviruses with a specific focus on the current outbreak in Wuhan, China. Furthermore, we discuss the clinical features and potential therapeutic options that may be effective against SARS-CoV-2.
Keywords: novel coronavirus; outbreak; therapeutics; transmission.
Copyright © 2020 American Society for Microbiology.
Similar articles
-
[Source of the COVID-19 pandemic: ecology and genetics of coronaviruses (Betacoronavirus: Coronaviridae) SARS-CoV, SARS-CoV-2 (subgenus Sarbecovirus), and MERS-CoV (subgenus Merbecovirus).].Vopr Virusol. 2020;65(2):62-70. doi: 10.36233/0507-4088-2020-65-2-62-70. Vopr Virusol. 2020. PMID: 32515561 Review. Russian.
-
COVID-19: The outbreak caused by a new coronavirus.Bol Med Hosp Infant Mex. 2020;77(2):47-53. doi: 10.24875/BMHIM.20000039. Bol Med Hosp Infant Mex. 2020. PMID: 32226003 Review. English.
-
The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?Int J Epidemiol. 2020 Jun 1;49(3):717-726. doi: 10.1093/ije/dyaa033. Int J Epidemiol. 2020. PMID: 32086938 Free PMC article.
-
Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV.J Microbiol Immunol Infect. 2020 Jun;53(3):365-367. doi: 10.1016/j.jmii.2020.02.001. Epub 2020 Feb 4. J Microbiol Immunol Infect. 2020. PMID: 32035811 Free PMC article. No abstract available.
-
The Novel Coronavirus: A Bird's Eye View.Int J Occup Environ Med. 2020 Apr;11(2):65-71. doi: 10.15171/ijoem.2020.1921. Epub 2020 Feb 5. Int J Occup Environ Med. 2020. PMID: 32020915 Free PMC article. Review.
Cited by
-
Multi-epitope vaccine design using in silico analysis of glycoprotein and nucleocapsid of NIPAH virus.PLoS One. 2024 May 10;19(5):e0300507. doi: 10.1371/journal.pone.0300507. eCollection 2024. PLoS One. 2024. PMID: 38728300 Free PMC article.
-
Challenges and opportunities of tele-speech therapy: Before and during the COVID-19 pandemic.J Public Health Res. 2024 Feb 7;13(1):22799036231222115. doi: 10.1177/22799036231222115. eCollection 2024 Jan. J Public Health Res. 2024. PMID: 38333616 Free PMC article. Review.
-
COVID-19 Pandemic: Therapeutic Strategies and Vaccines.Int J Mol Sci. 2023 Dec 31;25(1):556. doi: 10.3390/ijms25010556. Int J Mol Sci. 2023. PMID: 38203727 Free PMC article.
-
Age-dependent immune responses in COVID-19-mediated liver injury: focus on cytokines.Front Endocrinol (Lausanne). 2023 Aug 15;14:1139692. doi: 10.3389/fendo.2023.1139692. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37654571 Free PMC article. Review.
-
Sustainable solutions for indoor pollution abatement during COVID phase: A critical study on current technologies & challenges.J Hazard Mater Adv. 2022 Aug;7:100097. doi: 10.1016/j.hazadv.2022.100097. Epub 2022 May 23. J Hazard Mater Adv. 2022. PMID: 37520799 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous